Yesterday, March 23, 2016, 65 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $249.20 to $12,675,000.00.

Highlighted Stocks Traded by Insiders:

Plug Power (PLUG) - FREE Research Report

Air Liquide Investissements d'Avenir et de Demonstration, who is Director at Plug Power, sold 13,015 shares at $1.98 on March 23, 2016. Following this transaction, the Director owned 39,324 shares meaning that the stake was reduced by 24.87% with the 13,015-share transaction.

Historical insider transactions for Plug Power go as follows:

  • 4-Week # shares sold: 13,281
  • 12-Week # shares bought: 32,218
  • 12-Week # shares sold: 13,281
  • 24-Week # shares bought: 32,218
  • 24-Week # shares sold: 13,281

The average volume for Plug Power has been 2.1 million shares per day over the past 30 days. Plug Power has a market cap of $374.6 million and is part of the technology sector and electronics industry. Shares are down 7.58% year-to-date as of the close of trading on Wednesday.

Plug Power Inc., an alternative energy technology provider, engages in the design, development, manufacture, and commercialization of fuel cell systems for the industrial off-road markets worldwide. Currently, there are 3 analysts who rate Plug Power a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PLUG - FREE

TheStreet Quant Ratings

rates Plug Power as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Plug Power Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

RealPage (RP) - FREE Research Report

Seren Capital, Ltd., who is 10% Owner at RealPage, sold 12,000 shares at $20.33 on March 23, 2016. Following this transaction, the 10% Owner owned 19.8 million shares meaning that the stake was reduced by 0.06% with the 12,000-share transaction.

The shares most recently traded at $19.74, down $0.59, or 2.99% since the insider transaction. Historical insider transactions for RealPage go as follows:

  • 4-Week # shares bought: 50,000
  • 4-Week # shares sold: 26,607
  • 12-Week # shares bought: 50,000
  • 12-Week # shares sold: 26,607
  • 24-Week # shares bought: 50,000
  • 24-Week # shares sold: 301,927

The average volume for RealPage has been 286,400 shares per day over the past 30 days. RealPage has a market cap of $1.6 billion and is part of the technology sector and computer software & services industry. Shares are down 10.96% year-to-date as of the close of trading on Wednesday.

RealPage, Inc. provides software and software-enabled services for the rental housing and vacation rental industries in the United States. Currently, there are 2 analysts who rate RealPage a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on RP - FREE

TheStreet Quant Ratings

rates RealPage as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

RealPage Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abiomed (ABMD) - FREE Research Report

Puhy Dorothy E, who is Director at Abiomed, sold 10,000 shares at $90.30 on March 23, 2016. Following this transaction, the Director owned 52,190 shares meaning that the stake was reduced by 16.08% with the 10,000-share transaction.

The shares most recently traded at $90.29, down $0.01, or 0.01% since the insider transaction. Historical insider transactions for Abiomed go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 17,376
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 17,376
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 17,376

The average volume for Abiomed has been 636,000 shares per day over the past 30 days. Abiomed has a market cap of $4.0 billion and is part of the health care sector and health services industry. Shares are up 1.41% year-to-date as of the close of trading on Wednesday.

ABIOMED, Inc. researches, develops, and sells medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company has a P/E ratio of 29.4. Currently, there are 6 analysts who rate Abiomed a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABMD - FREE

TheStreet Quant Ratings

rates Abiomed as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and good cash flow from operations. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Abiomed Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.